Dexamethasone prodrug nanomedicine (ZSJ-0228) treatment significantly reduces lupus nephritis in mice without measurable side effects

Dexamethasone prodrug nanomedicine (ZSJ-0228) treatment significantly reduces lupus nephritis in mice without measurable side effects — A 5-month study

Published:2021-01 Issue: Volume:31 Page:102302
ISSN:1549-9634
Container-title:Nanomedicine: Nanotechnology, Biology and Medicine
language:en
Short-container-title:Nanomedicine: Nanotechnology, Biology and Medicine

Author:

Zhao Zhifeng,Jia Zhenshan,Foster Kirk W.,Wei Xin,Qiao Fangfang,Jiang Haochen,Jin Yan,Li Guojuan,Chen Ningrong,Zhao Gang,Thiele Geoffrey M.,Medlin Jennifer L.,O’Dell James R.,Wang Dong

Funder

National Institute of Allergy and Infectious Diseases of the National Institutes of Health

College of Pharmacy, University of Nebraska Medical Center

China Scholarship Council

Publisher

Elsevier BV

Subject

Pharmaceutical Science,General Materials Science,Biomedical Engineering,Molecular Medicine,Medicine (miscellaneous),Bioengineering

Reference43 articles.

1. Systemic lupus erythematosus;Kaul;Nat Rev Dis Primers.,2016

2. Taming lupus-a new understanding of pathogenesis is leading to clinical advances;Liu;Nat Med.,2012

3. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program;Somers;Arthritis Rheumatol.,2014